Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1992 1
1993 2
1994 6
1995 3
1996 5
1997 2
1998 1
2000 2
2001 1
2007 1
2008 3
2009 1
2011 5
2012 5
2013 6
2014 6
2015 4
2016 11
2017 11
2018 11
2019 8
2020 14
2021 18
2022 20
2023 24
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for p tau singh
Search for P Tara Singh instead (2 results)
Neuronal identity defines alpha-synuclein and tau toxicity.
Praschberger R, Kuenen S, Schoovaerts N, Kaempf N, Singh J, Janssens J, Swerts J, Nachman E, Calatayud C, Aerts S, Poovathingal S, Verstreken P. Praschberger R, et al. Neuron. 2023 May 17;111(10):1577-1590.e11. doi: 10.1016/j.neuron.2023.02.033. Epub 2023 Mar 21. Neuron. 2023. PMID: 36948206 Free PMC article.
Pathogenic alpha-synuclein and tau are critical drivers of neurodegeneration, and their mutations cause neuronal loss in patients. ...We detect phenotypic and transcriptomic evidence of differential neuronal vulnerability independent of alpha-synuclein or tau expres …
Pathogenic alpha-synuclein and tau are critical drivers of neurodegeneration, and their mutations cause neuronal loss in patients. .. …
Retinal Degeneration and Alzheimer's Disease: An Evolving Link.
Ashok A, Singh N, Chaudhary S, Bellamkonda V, Kritikos AE, Wise AS, Rana N, McDonald D, Ayyagari R. Ashok A, et al. Int J Mol Sci. 2020 Oct 2;21(19):7290. doi: 10.3390/ijms21197290. Int J Mol Sci. 2020. PMID: 33023198 Free PMC article. Review.
The cardinal features of AD include extracellular accumulation of amyloid beta (Abeta) and intracellular deposits of hyper-phosphorylated tau (p-tau). Neuroinflammation and brain iron dyshomeostasis accompany Abeta and p-tau deposits and, togeth …
The cardinal features of AD include extracellular accumulation of amyloid beta (Abeta) and intracellular deposits of hyper-phosphorylated …
Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease.
Chatterjee P, Pedrini S, Ashton NJ, Tegg M, Goozee K, Singh AK, Karikari TK, Simrén J, Vanmechelen E, Armstrong NJ, Hone E, Asih PR, Taddei K, Doré V, Villemagne VL, Sohrabi HR, Zetterberg H, Masters CL, Blennow K, Martins RN. Chatterjee P, et al. Alzheimers Dement. 2022 Jun;18(6):1141-1154. doi: 10.1002/alz.12447. Epub 2021 Sep 8. Alzheimers Dement. 2022. PMID: 34494715
INTRODUCTION: This study involved a parallel comparison of the diagnostic and longitudinal monitoring potential of plasma glial fibrillary acidic protein (GFAP), total tau (t-tau), phosphorylated tau (p-tau181 and p-tau231), and neurofilament li …
INTRODUCTION: This study involved a parallel comparison of the diagnostic and longitudinal monitoring potential of plasma glial fibrillary a …
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Patel MR, et al. N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10. N Engl J Med. 2011. PMID: 21830957 Free article. Clinical Trial.
RESULTS: In the primary analysis, the primary end point occurred in 188 patients in the rivaroxaban group (1.7% per year) and in 241 in the warfarin group (2.2% per year) (hazard ratio in the rivaroxaban group, 0.79; 95% confidence interval [CI], 0.66 to 0.96; P<0.001 f …
RESULTS: In the primary analysis, the primary end point occurred in 188 patients in the rivaroxaban group (1.7% per year) and in 241 in the …
Astrocytic interleukin-3 programs microglia and limits Alzheimer's disease.
McAlpine CS, Park J, Griciuc A, Kim E, Choi SH, Iwamoto Y, Kiss MG, Christie KA, Vinegoni C, Poller WC, Mindur JE, Chan CT, He S, Janssen H, Wong LP, Downey J, Singh S, Anzai A, Kahles F, Jorfi M, Feruglio PF, Sadreyev RI, Weissleder R, Kleinstiver BP, Nahrendorf M, Tanzi RE, Swirski FK. McAlpine CS, et al. Nature. 2021 Jul;595(7869):701-706. doi: 10.1038/s41586-021-03734-6. Epub 2021 Jul 14. Nature. 2021. PMID: 34262178 Free PMC article.
The influence of glial cells on the accumulation and clearance of beta-amyloid (Abeta) and neurofibrillary tau in the brains of individuals with Alzheimer's disease (AD) is poorly understood, despite growing awareness that these are therapeutically important interactions(4 …
The influence of glial cells on the accumulation and clearance of beta-amyloid (Abeta) and neurofibrillary tau in the brains of indiv …
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Secondary outcome measures included findings on positron-emission tomographic amyloid imaging with the use of Pittsburgh compound B (PIB-PET) and cerebrospinal fluid phosphorylated tau (phospho-tau) concentrations. RESULTS: There were no significant between-group di …
Secondary outcome measures included findings on positron-emission tomographic amyloid imaging with the use of Pittsburgh compound B (PIB-PET …
Plasma Abeta42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P, Pedrini S, Doecke JD, Thota R, Villemagne VL, Doré V, Singh AK, Wang P, Rainey-Smith S, Fowler C, Taddei K, Sohrabi HR, Molloy MP, Ames D, Maruff P, Rowe CC, Masters CL, Martins RN; AIBL Research Group. Chatterjee P, et al. Alzheimers Dement. 2023 Apr;19(4):1117-1134. doi: 10.1002/alz.12724. Epub 2022 Jul 21. Alzheimers Dement. 2023. PMID: 36574591
AUC of Abeta42/40+p-tau181+GFAP panel AUC of Abeta42/40/p-tau181/GFAP/NfL for Abeta-/+. ...Abeta42/40, p-tau181, GFAP, and NfL are associated with prospective cognitive decline. ...
AUC of Abeta42/40+p-tau181+GFAP panel AUC of Abeta42/40/p-tau181/GFAP/NfL for Abeta-/+. ...Abeta42/40, p-tau181, GFAP, …
Crocetin promotes clearance of amyloid-β by inducing autophagy via the STK11/LKB1-mediated AMPK pathway.
Wani A, Al Rihani SB, Sharma A, Weadick B, Govindarajan R, Khan SU, Sharma PR, Dogra A, Nandi U, Reddy CN, Bharate SS, Singh G, Bharate SB, Vishwakarma RA, Kaddoumi A, Kumar A. Wani A, et al. Autophagy. 2021 Nov;17(11):3813-3832. doi: 10.1080/15548627.2021.1872187. Epub 2021 Jan 19. Autophagy. 2021. PMID: 33404280 Free PMC article.
Alzheimer disease (AD) is usually accompanied by two prominent pathological features, cerebral accumulation of amyloid-beta (Abeta) plaques and presence of MAPT/tau neurofibrillary tangles. Dysregulated clearance of Abeta largely contributes to its accumulation and plaque …
Alzheimer disease (AD) is usually accompanied by two prominent pathological features, cerebral accumulation of amyloid-beta (Abeta) plaques …
Di-chlorido-(4-methyl-aniline-κN)[N-(4-methyl-phen-yl)-1-(thio-phen-2-yl)methanimine-κN]palladium(II).
Butcher RJ, Singh P, Shabbani G. Butcher RJ, et al. Acta Crystallogr E Crystallogr Commun. 2022 May 17;78(Pt 6):629-632. doi: 10.1107/S2056989022004960. eCollection 2022 Jun 1. Acta Crystallogr E Crystallogr Commun. 2022. PMID: 36072135 Free PMC article.
The structure of a mono-amine Pd(II) complex, [PdCl(2)(C(7)H(9)N)(C(12)H(11)NS)], which crystallizes in the triclinic space group, P , is reported. The primary geometry around the Pd(II) atom closely resembles square planar (tau(4)' = 0.069). In the (E)-1-(thio-phen …
The structure of a mono-amine Pd(II) complex, [PdCl(2)(C(7)H(9)N)(C(12)H(11)NS)], which crystallizes in the triclinic space group, P …
Anti-tau antibodies targeting a conformation-dependent epitope selectively bind seeds.
Hitt BD, Gupta A, Singh R, Yang T, Beaver JD, Shang P, White CL 3rd, Joachimiak LA, Diamond MI. Hitt BD, et al. J Biol Chem. 2023 Nov;299(11):105252. doi: 10.1016/j.jbc.2023.105252. Epub 2023 Sep 14. J Biol Chem. 2023. PMID: 37714465 Free PMC article.
Neurodegenerative tauopathies are caused by the transition of tau protein from a monomer to a toxic aggregate. They include Alzheimer disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and Pick disease (PiD). ...We proposed that cis/trans …
Neurodegenerative tauopathies are caused by the transition of tau protein from a monomer to a toxic aggregate. They include Alzheimer …
169 results